HK1202243A1 - Methods for improving cognitive function and decreasing heart rate - Google Patents

Methods for improving cognitive function and decreasing heart rate Download PDF

Info

Publication number
HK1202243A1
HK1202243A1 HK15102730.4A HK15102730A HK1202243A1 HK 1202243 A1 HK1202243 A1 HK 1202243A1 HK 15102730 A HK15102730 A HK 15102730A HK 1202243 A1 HK1202243 A1 HK 1202243A1
Authority
HK
Hong Kong
Prior art keywords
dha
acid
dosage form
subject
memory
Prior art date
Application number
HK15102730.4A
Other languages
English (en)
Chinese (zh)
Inventor
‧尤科-毛羅
K‧尤科-毛罗
Original Assignee
帝斯曼知识产权资产有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 帝斯曼知识产权资产有限公司 filed Critical 帝斯曼知识产权资产有限公司
Publication of HK1202243A1 publication Critical patent/HK1202243A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
HK15102730.4A 2009-02-02 2015-03-17 Methods for improving cognitive function and decreasing heart rate HK1202243A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14931009P 2009-02-02 2009-02-02
US61/149,310 2009-02-02
US18354809P 2009-06-02 2009-06-02
US61/183,548 2009-06-02

Publications (1)

Publication Number Publication Date
HK1202243A1 true HK1202243A1 (en) 2015-09-25

Family

ID=42041547

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102730.4A HK1202243A1 (en) 2009-02-02 2015-03-17 Methods for improving cognitive function and decreasing heart rate

Country Status (8)

Country Link
US (2) US20100203123A1 (enExample)
EP (2) EP2391361A1 (enExample)
JP (5) JP2012516852A (enExample)
CN (3) CN102365087A (enExample)
AU (2) AU2016201382A1 (enExample)
CA (1) CA2751275A1 (enExample)
HK (1) HK1202243A1 (enExample)
WO (1) WO2010088700A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
CN103732223A (zh) * 2011-05-19 2014-04-16 加利福尼亚大学董事会 用于认知能力下降的医疗食品
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US20130084272A1 (en) * 2011-09-29 2013-04-04 Philippe Perrin Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
CA2903599A1 (en) * 2013-03-15 2014-09-18 Genspera, Inc. Methods for making cancer compositions
KR102416853B1 (ko) 2013-12-20 2022-07-05 마라 리뉴어블즈 코퍼레이션 미생물로부터 오일을 회수하는 방법
TR201503136A2 (tr) * 2015-03-16 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve esansiyel yağ asitlerinin farmasötik kompozisyonları.
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
EP3559206B1 (en) 2016-12-22 2025-12-03 Mara Renewables Corporation Methods for producing biomass rich in dha, palmitic acid and protein using a eukaryotic microorganism
JP7101087B2 (ja) * 2018-09-05 2022-07-14 株式会社 伊藤園 軽度認知障害に対する緑茶成分の有効性評価方法
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
CN114555074A (zh) * 2019-08-08 2022-05-27 斯威本科技大学 长链多不饱和脂肪酸的用途
KR20220163979A (ko) 2020-04-03 2022-12-12 마라 리뉴어블즈 코퍼레이션 높은 수준의 오메가-3 지방산을 갖는 미생물 오일
DE102020115238A1 (de) * 2020-06-09 2021-12-09 Pm-International Ag Nahrungsergänzungsmittel und Nahrungsmittel
EP4176448A1 (en) * 2020-07-02 2023-05-10 Pear Therapeutics (US), Inc. Systems, methods, and devices for generating and administering digital therapeutic placebos and shams
CA3204546A1 (en) * 2021-01-15 2022-07-21 Cambridge Cognition Limited Methods and systems of identifying individuals for perioperative neurocognitive disorder and/or post-viral cognitive impairment
EP4637824A1 (en) * 2023-01-18 2025-10-29 Bioventures, Llc Method of preventing and treating alzheimer's disease and related dementias with drugs inhibiting the interaction between 14-3-3g protein and hexokinase-1 protein
JP2025079778A (ja) * 2023-11-10 2025-05-22 ダイドーグループホールディングス株式会社 生理機能改善用の組成物
WO2025100476A1 (ja) * 2023-11-10 2025-05-15 国立大学法人京都大学 生理機能改善用の組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
CA2164291C (en) * 1993-06-09 2007-10-30 David John Kyle Methods and pharmaceutical compositions useful for treating neurological disorders
US5928696A (en) 1994-08-16 1999-07-27 Dr. Frische Gmbh Process for extracting native products which are not water-soluble from native substance mixtures by centrifugal force
AU5346296A (en) * 1995-04-17 1996-11-07 Japan As Represented By Director-General Of Agency Of Industrial Science And Technology Novel microorganisms capable of producing highly unsaturated fatty acids and process for producing highly unsaturated fa tty acids by using the microorganisms
JP3985035B2 (ja) * 1995-09-14 2007-10-03 独立行政法人産業技術総合研究所 （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途
WO2000050547A1 (en) 1999-02-26 2000-08-31 Monsanto Company Process for separating a triglyceride comprising a docosahexaenoic acid residue from a mixture of triglycerides
AU2001232786A1 (en) 2000-01-11 2001-07-24 Monsanto Company Process for making an enriched mixture of polyunsaturated fatty acid esters
RU2336307C2 (ru) 2000-01-19 2008-10-20 Мартек Биосайнсис Корпорейшн Способ получения липидов (варианты) и липиды, полученные этим способом
EP1272048B1 (en) 2000-04-12 2008-05-21 Westfalia Separator GmbH Method for the fractionation of oil and polar lipid-containing native raw materials
CA2446059C (en) 2001-05-14 2010-03-23 Dsm Ip Assets B.V. Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes
AU2002309856B2 (en) 2001-05-14 2008-10-23 Dsm Ip Assets B.V. Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
AU2002320251A1 (en) * 2001-07-05 2003-01-21 Vital Basics, Inc. Compositions for improving mental performance
WO2003092628A2 (en) 2002-05-03 2003-11-13 Martek Biosciences Corporation High-quality lipids and methods for producing by enzymatic liberation from biomass
US20090054523A1 (en) * 2005-01-24 2009-02-26 Morten Bryhn Use of a Fatty Acid Composition Containing DHA for the Production of a Medical Product or a Food Stuff for the Treatment of Amyloidos-Related Diseases
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
EP1888081B1 (en) * 2005-05-23 2016-12-28 Massachusetts Institute of Technology Compositions containing pufa and methods of use thereof
BRPI0613358A8 (pt) * 2005-07-08 2017-12-26 Dsm Ip Assets Bv ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
WO2009002145A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
JP2010532418A (ja) 2007-06-29 2010-10-07 マーテック バイオサイエンシーズ コーポレーション 多価不飽和脂肪酸のエステルの製造方法および精製方法
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid

Also Published As

Publication number Publication date
EP2939671A1 (en) 2015-11-04
US20100203123A1 (en) 2010-08-12
EP2391361A1 (en) 2011-12-07
AU2016201382A1 (en) 2016-03-24
JP2020050675A (ja) 2020-04-02
CN104042600A (zh) 2014-09-17
CN108324706A (zh) 2018-07-27
JP2015143248A (ja) 2015-08-06
CA2751275A1 (en) 2010-08-05
US20130172412A1 (en) 2013-07-04
AU2010207929A1 (en) 2011-09-22
JP2012516852A (ja) 2012-07-26
JP2018104477A (ja) 2018-07-05
JP2022059063A (ja) 2022-04-12
AU2017245327A1 (en) 2017-11-02
WO2010088700A1 (en) 2010-08-05
CN102365087A (zh) 2012-02-29

Similar Documents

Publication Publication Date Title
HK1202243A1 (en) Methods for improving cognitive function and decreasing heart rate
JP6419927B2 (ja) 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
US11413263B2 (en) Reducing the risk of pathological effects of traumatic brain injury
ES2661217T3 (es) Composiciones y métodos para reducir los triglicéridos sin aumentar los niveles de LDL-C en un sujeto en terapia simultánea con estatinas
ES2750365T3 (es) Composición para el tratamiento y/o la prevención de enfermedades cardiovasculares
US20140357717A1 (en) Methods of treating hypertriglyceridemia
US20110086914A1 (en) Methods for Treating Traumatic Brain Injury
US20110177061A1 (en) Methods of treating and preventing neurological disorders using docosahexaenoic acid
AU2010207929B2 (en) Methods for improving cognitive function and decreasing heart rate
HK1172241B (en) Reducing the risk of pathological effects of traumatic brain injury
HK1172241A (en) Reducing the risk of pathological effects of traumatic brain injury